Initial serum (1,3)-β-d-glucan as a predictor of mortality in proven candidaemia: Findings from a retrospective study in two teaching hospitals in Italy and Brazil

Clinical Microbiology and Infection

Volumn 21, Issue 10, 2015, Pages 954.e9-954.e17

  Giacobbe, D R ^a   Esteves, P ^b   Bruzzi, P ^a   Mikulska, M ^a   Furfaro, E ^a   Mesini, A ^a   Tatarelli, P ^a   Grignolo, S ^a   Viscoli, C ^a   Colombo, A L ^b   Del Bono, V ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bloodstream infections; Candida spp.; Candidaemia; Mortality; d glucan

Indexed keywords

BETA 1,3 GLUCAN; BETA GLUCAN; BETA-1,3-D-GLUCAN; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BLOOD CULTURE; BRAZIL; CANDIDEMIA; FEMALE; HEMODIALYSIS; HUMAN; ITALY; MALE; MORTALITY; NONHUMAN; PITT SCORE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TEACHING HOSPITAL; BLOOD; CHEMISTRY; DECISION SUPPORT SYSTEM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SERUM; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BETA-GLUCANS; BIOMARKERS; BRAZIL; CANDIDEMIA; DECISION SUPPORT TECHNIQUES; FEMALE; HOSPITALS, TEACHING; HUMANS; ITALY; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SERUM; SURVIVAL ANALYSIS;

EID: 84942134663     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2015.06.002     Document Type: Article

References (31)

1. Falagas M.E., Apostolou K.E., Pappas V.D. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 2006, 25:419-425.
2. Zaoutis T.E., Argon J., Chu J., Berlin J.A., Walsh T.J., Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005, 41:1232-1239.
3. Arendrup M.C., Fuursted K., Gahrn-Hansen B., Schonheyder H.C., Knudsen J.D., Jensen I.M., et al. Semi-national surveillance of fungaemia in Denmark, 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin Microbiol Infect 2008, 14:487-494.
4. Arendrup M.C., Bruun B., Christensen J.J., Fuursted K., Johansen H.K., Kjaeldgaard P., et al. National surveillance of fungemia in Denmark (2004 to 2009). J Clin Microbiol 2011, 49:325-334.
5. Fernandez J., Erstad B.L., Petty W., Nix D.E. Time to positive culture and identification for Candida blood stream infections. Diagn Microbiol Infect Dis 2009, 64:402-407.
6. Morrell M., Fraser V.J., Kollef M.H. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005, 49:3640-3645.
7. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
8. Cuenca-Estrella M., Verweij P.E., Arendrup M.C., Arikan-Akdagli S., Bille J., Donnelly J.P., et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect 2012, 18(Suppl. 7):9-18.
9. Del Bono V., Delfino E., Furfaro E., Mikulska M., Nicco E., Bruzzi P., et al. Clinical performance of the (1,3)-β-d-glucan assay in early diagnosis of nosocomial Candida bloodstream infections. Clin Vaccine Immunol 2011, 18:2113-2117.
10. Posteraro B., De Pascale G., Tumbarello M., Torelli R., Pennisi M.A., Bello G., et al. Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1→3)-β-d-glucan assay, Candida score, and colonization index. Crit Care 2011, 15:R249.
11. Jaijakul S., Vazquez J.A., Swanson R.N., Ostrosky-Zeichner L. (1,3)-β-d-Glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis 2012, 55:521-526.
12. Pazos C., Moragues M.D., Quindos G., Ponton J., del Palacio A. Diagnostic potential of (1,3)-beta-d-glucan and anti-Candida albicans germ tube antibodies for the diagnosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients. Rev Iberoam Micol 2006, 23:209-215.
13. Senn L., Robinson J.O., Schmidt S., Knaup M., Asahi N., Satomura S., et al. 1,3-beta-d-Glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008, 46:878-885.
14. Pazos C., Ponton J., Del Palacio A. Contribution of (1→3)-beta-d-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005, 43:299-305.
15. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
16. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
17. Rhee J.Y., Kwon K.T., Ki H.K., Shin S.Y., Jung D.S., Chung D.R., et al. Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the Acute Physiology and Chronic Health Evaluation II scoring systems. Shock 2009, 31:146-150.
18. Odabasi Z., Mattiuzzi G., Estey E., Kantarjian H., Saeki F., Ridge R.J., et al. beta-d-Glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004, 39:199-205.
19. Fisher C.E., Stevens A.M., Leisenring W., Pergam S.A., Boeckh M., Hohl T.M. The serum galactomannan index predicts mortality in hematopoietic stem cell transplant recipients with invasive aspergillosis. Clin Infect Dis 2013, 57:1001-1004.
20. Mikulska M., Raiola A.M., Signori A., Furfaro E., Del Bono V., Bacigalupo A., et al. Screening with serum galactomannan might be associated with better outcome than symptom-triggered galactomannan testing in allogeneic HSCT recipients with invasive aspergillosis. Clin Infect Dis 2013, 57:1786-1787.
21. Shimizu A., Oka H., Matsuda T., Ozaki S. (1→3)-beta-d-Glucan is a diagnostic and negative prognostic marker for Pneumocystis carinii pneumonia in patients with connective tissue disease. Clin Exp Rheumatol 2005, 23:678-680.
22. Watanabe T., Yasuoka A., Tanuma J., Yazaki H., Honda H., Tsukada K., et al. Serum (1→3)beta-d-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis 2009, 49:1128-1131.
23. Koga M., Koibuchi T., Kikuchi T., Nakamura H., Miura T., Iwamoto A., et al. Kinetics of serum beta-d-glucan after Pneumocystis pneumonia treatment in patients with AIDS. Intern Med 2011, 50:1397-1401.
24. Sims C.R., Jaijakul S., Mohr J., Rodriguez J., Finkelman M., Ostrosky-Zeichner L. Correlation of clinical outcomes with β-glucan levels in patients with invasive candidiasis. J Clin Microbiol 2012, 50:2104-2106.
25. Blot S.I., Vandewoude K.H., Hoste E.A., Colardyn F.A. Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 2002, 113:480-485.
26. Colombo A.L., Guimarães T., Sukienik T., Pasqualotto A.C., Andreotti R., Queiroz-Telles F., et al. Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Med 2014, 40:1489-1498.
27. Kojic E.M., Darouiche R.O. Candida infections of medical devices. Clin Microbiol Rev 2004, 17:255-267.
28. Uzun O., Ascioglu S., Anaissie E.J., Rex J.H. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin Infect Dis 2001, 32:1713-1717.
29. Andes D.R., Safdar N., Baddley J.W., Playford G., Reboli A.C., Rex J.H., et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012, 54:1110-1122.
30. Nett J.E., Sanchez H., Cain M.T., Andes D.R. Genetic basis of Candida biofilm resistance due to drug sequestering matrix glucan. J Infect Dis 2010, 202:171-175.
31. Lortholary O., Renaudat C., Sitbon K., Madec Y., Denoeud-Ndam L., Wolff M., et al. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med 2014, 40:1303-1312.